Merck: raises annual target ranges

(CercleFinance.com) - On its quarterly earnings call, Merck announces that it has raised and tightened its target ranges for adjusted EPS and revenues for FY 2024, expecting them from $8.
53 to $8.65 and from $63.1 to $64.3 billion respectively.

For Q1, the pharmaceutical company posted non-GAAP EPS that is up 48% to $2.07, on sales of close to $15.8bn, up 9% (+12% excluding currency effects).

Merck highlights continued strong revenue growth in oncology and vaccines, with currency-adjusted increases of 24% for its blockbuster Keytruda and 17% for its Gardasil/Gardasil 9 franchise.


Copyright (c) 2024 CercleFinance.com. All rights reserved.